LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

Strona główna・Stock List・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Closed

SectorHealthcare

14.32 -0.14

Buy Sell

Overview

Share price change

24h

Current

Min

14.31

Max

14.34

Key metrics
By Trading Economics
Income	-16M 1.7M
Sales	16M 185M
Profit margin	0.912
Employees	499
EBITDA	-43M 5M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-1.81% downside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	16M 4.5B
Previous open	14.46
Previous close	14.32

News Sentiment

By Acuity

10%

90%

6 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

5.925 / 7.38 Support & Resistance

Amicus Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 gru 2025, 14:38 UTC

Earnings

Hot Stocks

Stocks to Watch Friday: Nike, Oracle, FedEx, Sony -- WSJ

Peer Comparison

Price change

Amicus Therapeutics Inc Forecast

Price Target

By TipRanks

-1.81% downside

12 Months Forecast

Average 14.08 USD -1.81%

High 14.5 USD

Low 12 USD

Based on 8 Wall Street analysts offering 12 month price targets forAmicus Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Amicus Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.925 / 7.38Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

6 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.